Dalotuzumab
As of the edition of 20 October 2026, Dalotuzumab is an antibody: went quiet in 2020; acts on IGF1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Antibody
- Registered trials
- 19, 3 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Hormones; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Dalotuzumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IGF1R | Insulin-like growth factor 1 receptor | P08069 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 10 | 9 | 0 | 1 |
| Phase 2 | 9 | 7 | 0 | 2 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2006 to now |